JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
13th January 2025 Uncategorised 0Against the backdrop of poor sales for the company’s COVID-19 shot Spikevax and its recently approved RSV prophylactic mRESVIA, Moderna is “accelerating and expanding” its prior efficiency and prioritization efforts. The company plans to hive off roughly $1 billion from its annual spend in 2025.
More: JPM25: Moderna slashes guidance, plots B in cost cuts this year amid lackluster vaccine sales
Source: fierce